We have updated our Sinclair Pharma forecasts to reflect the change in financial year-end from 30th June to 31st December. We maintain our Buy recommendation and 42p target price, supported in particular by the imminent US launch of Silhouette Instalift™, for which strong demand for practitioner training has been reported by Sinclair’s US partner Thermigen (a subsidiary of Almirall), and the continued strong in-market performance of Ellansé®.
